Your healthcare agency is receiving this information packet as an accompaniment to your delivery of JYNNEOS™ vaccine. Please be aware the NH vaccine supply remains severely limited, and we do not have a clear indication of how many doses we will receive in the future. Therefore, we ask you to prioritize vaccination for those most susceptible for monkeypox, and retain some vaccine for use as PEP. To help manage the expected high demand with a limited supply, please ensure the following:

- Retain and manage enough inventory to administer both first and second doses to individuals you are vaccinating.
- Unless otherwise specified, the doses allocated to your agency are for both the first and second dose. Ensure you do not use all of these doses for first doses, as there is limited supply to cover your second doses at this time.
- Schedule the second dose appointment during the first dose appointment before the individual leaves your clinical site.
- Maintain a minimum of two vials (10 intradermal courses or 2 subcutaneous doses) for PEP clients directed to your location by the NH Division of Public Health Services.
- Please notify the NH Immunization Program at (603) 271-4463 if your inventory of JYNNEOS™ vaccine drops below a level where your agency does not have sufficient supply to administer first doses to request additional vaccine. We will supply additional vaccine as available. If supply is not available to fulfill your request, we may ask your clinic to suspend PrEP vaccination until additional doses become available.

The enclosed materials are to provide guidance to ensure proper vaccine storage/handling, safe vaccine administration and accurate documentation of administration, as well as to provide support information about the JYNNEOS™ vaccine for staff reference.

Contents of this packet:

- **Immediate Attention:** JYNNEOS™ Storage and Handling Guidelines
- Medical Screening Questions Template
- Adding and receiving JYNNEOS™ vaccine to inventory
- JYNNEOS™ Vaccine Administration Instructions
- Documenting a JYNNEOS™ Dose in NH IIIS
- NHIP Vaccine Card: vaccine card for healthcare providers to complete and give to the individual after administering the JYNNEOS™ vaccine (optional if there is already a way for the individual to gain access to this information).

Note: All adults that receive the JYNNEOS™ vaccine intradermally and all children (less than 18 years of age) that receive the vaccine subcutaneously should receive the EUA fact sheet. Any adult that receives the vaccine subcutaneously should receive the VIS. The EUA and VIS can be accessed using the links in Additional Resources below.

Additional Resources:
- CDC Monkeypox FAQ: https://www.cdc.gov/poxvirus/monkeypox/faq.html
- CDC Monkeypox Vaccination Strategies: https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/overview.html#anchor_41663
- EUA JYNNEOS™ Health Care Provider Fact Sheet: https://www.fda.gov/media/160774/download
- EUA JYNNEOS™ Health Care Recipient/Caregiver Fact Sheet: https://www.fda.gov/media/160774/download
- JYNNEOS™ Package Insert - – JYNNEOS™ vaccine manufacturer instructions (vaccine package insert) NOTE: Additional storage and handling information has been released since these instructions. NHIP’s JYNNEOS™-Storage and Handling Guidelines should be utilized and supersede the package insert instructions. https://www.fda.gov/media/160774/download
- CDC Recommendations for Use of the JYNNEOS™ Vaccine: JYNNEOS™ Vaccine | Monkeypox | Poxvirus | CDC . (https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#resources)
- CDC What’s New & Updated: https://www.cdc.gov/poxvirus/monkeypox/whats-new.html

Please contact the New Hampshire Immunization Program with any further questions.
- New Hampshire Immunization Program: 603-271-4482 or Immunization@dhhs.nh.gov
- NHIIS-related: nhiis.support@dhhs.nh.gov
Vaccine Storage

1. If the vaccine is **frozen** when received and you must store vaccine before use, you may:
   a. **Keep frozen** (-25°C to -15°C), in standard freezer storage. Do not store JYNNEOS™ at temperatures below -25°C (-13°F). If stored frozen, the vaccine should be used within the printed expiration date on the carton. **Note:** The expiration date is **not** on the individual vial.

   OR

   b. **Store in a refrigerator** at +2°C to +8°C (+36°F to +46°F) for up to 8 weeks, from thawing. You must label vials with an 8-week expiration date (from date of thaw). **Do not refreeze.**

2. If vaccines are refrigerated (+2°C to +8°C) when received and storage is required before use:
   a. Refrigerate at +2°C to +8°C. NH Immunization Program staff will give providers an updated expiration date. Label vials with this expiration date. **Do not refreeze.**

   **Important Note:** The vaccine manufacturer provided the above information based on available supportive stability data. **Please be aware this differs from the STORAGE and USE BY period of 12 hours once thawed, and is found in the JYNNEOS™ package insert (Sections 2.2. Preparation and Administration and 16.2 Storage Conditions).**

3. When used for intradermal injection, up to five (5) doses of 0.1mL may be used from a single vial. Once the vial is punctured and a dose withdrawn, and not used in its entirety, store at +2°C to +8°C (+36°F to +46°F) and discarded within 8 hours of the first puncture.

4. Store in the original package to protect from light. If the original package is not available, keep vial in light-sensitive bag.

5. If vaccine temperatures go out of range, label exposed vaccines with “Do Not Use”, and store them under proper condition as soon as possible. Do not discard vaccines unless directed to by your state/local health dept. and/or the manufacturer.

**Instructions for Receiving JYNNEOS™ Vaccine from the NH Immunization Program (NHIP)**

**Via UPS**

a. NHIP staff will pack vaccines with cold packs, bubble wrap, and packing slip.

b. NHIP staff will provide UPS tracking# via email, once shipped.
c. Upon receipt, verify quantity and LOT# with packing slip, and immediately store vaccines in a refrigerator between +2C to +8C, as the vaccine has started to thaw during shipping (see applicable guidelines above, Vaccine Storage 1b). **Do not store in standard freezer.**

d. Return thermal shipping cooler with cold packs back to NHIP within seven business days. UPS return label will be included in the shipment.

**Via Courier**

a. Couriers will call provider Point of Contact (POC) staff once they are on the way to transport vaccines to inform about estimated time of arrival and determine a meeting location (lobby, etc.).

b. Once couriers reach the destination, POC will be informed and meet transport at the established meeting location.

c. Couriers will follow POC to their vaccine storage and complete the transfer of vaccine directly to the POC’s permanent storage (refrigerator or freezer).
   
   - Couriers will give vaccines, from the insulated container, and the chain of custody (COC) form to POC.
   
   - POC will place vaccines in permanent storage, fill out information on yellow copy of COC, keeping the yellow copy, and the couriers will keep pink copy.

d. Courier will inform POC how the vaccines were transported, as frozen or refrigerated, and POC will store vaccines in the appropriate and available storage. (see applicable instructions, Vaccine Storage 1-2a on page one)

**Via Direct-Ship from Strategic National Stockpile (SNS)**

a. Once you place a vaccine order for direct-shipment, SNS will provide a tracking number and methodology.

b. Once you receive the vaccine shipment, open the box.

c. Check the **TempTale 4** monitor: Press and hold the STOP button for 1-3 seconds until the “Stop Sign” icon appears in the upper right corner of the LCD display (see picture below).
d. If temperature displayed on TempTale 4 monitor is between -25C to -15C, store vaccines in a standard freezer (see applicable instructions 1 thru 2a on previous page).

e. When the TempTale 4 is exposed to a temperature outside a pre-programmed time and temperature limit threshold, an “Alarm Bell” icon will appear in the lower right corner of the display (see picture above). Store in a refrigerator ONLY, between +2C to +8C, as the vaccine has started to thaw during shipping (see applicable instructions, Vaccine Storage 1-2a on page one).

f. If the stopped recording and/or the limits exceeded icons are already on, immediately place the vaccine in the refrigerator for storage and follow the instructions below:

   I. Press and release the START button. The “Arrow” icon will appear temporarily in the lower left corner and the temperature history information will appear on the display in this order:

   **NOTE: You will need to document the information below and it will display rapidly.**

   1. Average temperature
   2. Highest temperature recorded
   3. Total time above high temperature limit
   4. Lowest temperature recorded
   5. Total time below low temperature limit

   g. Contact the NH Immunization Program for assistance with the documented information above, via phone, 603-271-4463, or via email, immunization@dhhs.nh.gov.

   h. If a packing slip was included in the shipment, scan it and email it to immunization@dhhs.nh.gov.

   i. If a return label was included with the shipment, pack the container (without vaccines) and place label on the top, hide existing labels, and process for return. If it was not included, that vaccine container can be disposed.
Monkeypox Virus Outbreak, Update #3

*JYNNEOS™ Vaccine and Tecovirimat (TPOXX) Access*

Key Points and Recommendations:

- Monkeypox virus infections are increasing in the United States and globally with spread of the virus occurring primarily through sexual networks affecting men who have sex with men (MSM); on July 23rd the World Health Organization (WHO) declared the escalating global outbreak a Public Health Emergency of International Concern (PHEIC).

- Recent studies have identified a median incubation period of ~7 days between exposure and onset of disease (*Thornhill et al. NEJM. Jul 2022*; *Tarín-Vicente et al. Lancet Pre-Print. Jul 2022*). Because of the short incubation period, post-exposure prophylaxis (PEP) vaccination is likely of lower benefit for disease control than identifying and vaccinating high-risk persons BEFORE exposure occurs. Therefore, NH Division of Public Health Services (DPHS) will continue to provide PEP but is also transitioning to a pre-exposure prevention vaccine strategy.

- NH DPHS recommends that the following highest-risk persons be vaccinated with JYNNEOS to protect against monkeypox virus infection:
  - Post-Exposure Prophylaxis (PEP) vaccination should be offered to:
    - Persons who report in the prior 14 days prolonged (i.e., hours of) face-to-face contact, or any direct physical/intimate contact to another person with suspect or confirmed monkeypox.
    - Persons who report in the prior 14 days coming into physical contact with items (e.g., clothing or linens) that are known to have previously touched the infectious rash or body fluids of a person with monkeypox.
    - Healthcare workers who in the prior 14 days have an exposure to monkeypox without wearing all recommended personal protective equipment (PPE), as outlined in CDC’s Exposure Risk Assessment tables.
  - Pre-Exposure Prophylaxis (PrEP) vaccination should be offered to men who have sex with men (MSM) that report any of the following:
    - 3 or more new sex partners in the last month;
    - Engaging in group or anonymous sex;
    - Engaging in sex with people at sex-on-site venues or events;
    - Exchanging sex for money, drugs, or other services; or
    - Taking medications for HIV prevention (i.e., HIV PrEP)
  - Persons can be vaccinated using NH vaccine supply if they are residents of NH, work in NH, or have a NH primary care provider.
  - Persons with confirmed monkeypox infection during the 2022 outbreak should NOT be vaccinated even if they meet the criteria above, because disease is likely to be protective.
• NH DPHS will provide JYNNEOS vaccine through city health departments and provider clinics that have agreed to receive referrals for vaccination from clinicians both in and outside their health system.
  o Information about clinic locations, availability, and contact/referral information can be found on the NH DPHS monkeypox website starting Monday, August 15th.
  o This website will be routinely updated as new clinic locations are added.

• Review CDC’s new Interim Guidance for use of the JYNNEOS vaccine.
  o The standard FDA-approved JYNNEOS dosing regimen for adults 18 years of age or older is 2 doses (0.5 mL per dose) administered by subcutaneous injection, separated by 28 days.
    - Provide the JYNNEOS Vaccine Information Statement (VIS) to all patients prior to vaccination occurring under the FDA-approved dosing regimen.
  o The FDA has also issued an Emergency Use Authorization (EUA) which allows the JYNNEOS vaccine to be given as follows:
    - Adults 18 years of age or older: 2 doses (0.1 mL per dose) administered by intradermal injection (doses separated by 28 days).
    - Children and adolescents younger than 18 years: 2 doses (0.5 mL per dose) administered by subcutaneous injection (doses separated by 28 days).
  o We recommend providers transition now to intradermal administration under the FDA’s EUA (for adults 18 years of age or older) because this dose-sparing strategy increases vaccine availability by 5-fold.
    - Review the FDA Fact Sheet for Healthcare Providers administering the JYNNEOS vaccine under the FDA’s EUA.
    - Provide the FDA Fact Sheet for Recipients and Caregivers being administered the JYNNEOS vaccine under the FDA’s EUA.
    - The lower intradermal dose has been studied and shown to be immunologically non-inferior to the standard subcutaneous dose.
    - Counsel patients about the risk for local injection site reactions (e.g., redness, swelling, induration, itching) which can potentially last for a prolonged period of time with intradermal administration.
    - Resources for administering an intradermal injection will be available on CDC’s website, and we will review intradermal injections on a Project ECHO webinar (see attached flyer).

• JYNNEOS is safe with few contraindications and precautions as summarized below.
  o Contraindication: Persons with a history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of JYNNEOS vaccine have a vaccine CONTRAINDICATION to receipt of a subsequent dose.
  o Precaution:
    - Persons with a previous severe allergic reaction to gentamicin or ciprofloxacin have a vaccine PRECAUTION because the JYNNEOS vaccine contains small amounts of gentamicin and ciprofloxacin.
- Persons with a previous severe allergic reaction to chicken or egg protein AND who are currently avoiding exposure to all chicken or egg products have a vaccine PRECAUTION because the vaccine is produced using chicken embryo cells.

- Persons with a vaccine PRECAUTION should be counseled about the potential increased risk of allergic reaction, and providers should discuss risks and benefits of vaccination. A 30-minute observation period after vaccination is recommended.

- The JYNNEOS vaccine is expected to be at least 85% effective at preventing monkeypox, based on historical data. Therefore, people who get vaccinated should continue to be counseled to take steps to protect themselves from monkeypox (see CDC’s prevention guidance).

- Review the following short CDC videos for a refresher on vaccine administration:
  - Intradermal vaccine administration
  - Subcutaneous vaccine administration

- Providers should be familiar with CDC’s Interim Clinical Guidance for the Treatment of Monkeypox.
  - Tecovirimat (TPOXX) is the primary therapeutic being used to treat monkeypox infection, including for outpatient therapy.
  - TPOXX can be accessed by a prescribing provider by contacting NH DPHS at: 603-271-4496.
  - Use of TPOXX to treat monkeypox virus infection occurs under a CDC Expanded Access Investigational New Drug (EA-IND) protocol, so providers must follow CDC’s requirements for obtaining and using TPOXX, including obtaining informed consent before treatment and submitting the required forms to CDC Regulatory Affairs at regaffairs@cdc.gov.
  - Review also CDC’s Guidance for Tecovirimat Use, FDA Package Insert, and SIGA Fact Sheet. UpToDate® online also has monkeypox and TPOXX information for clinicians.

- Testing for monkeypox is available at our NH public health laboratories (PHL) and five commercial reference laboratories. To request testing at our NH PHL, clinicians should first contact NH DPHS by calling 603-271-4496 (after hours 603-271-5300 and ask for the public health professional on call). Clinicians do NOT need to report testing that is occurring through commercial laboratories.

- Test for other sexually transmitted infections (STIs) in addition to monkeypox, because multiple studies (Girometti et al. Lancet Infect Dis. Jul 2022; Thornhill et al. NEJM. Jul 2022; Tarin-Vicente et al. Lancet Pre-Print. Jul 2022) have found that 17-29% of people diagnosed with monkeypox have concomitant STIs, including chlamydia, gonorrhea, and syphilis.

- Clinicians should immediately report any confirmed case of monkeypox to NH DPHS by calling 603-271-4496 (after hours 603-271-5300 and ask for the public health professional on call).

- Join our monthly NH DPHS healthcare provider webinar for additional monkeypox updates; the next webinar will be on Thursday, 8/11 from 12:00 – 1:00 pm:
  - Zoom link: https://nh-dhhs.zoom.us/s/94059287404
  - Call-in phone number: (646) 558-8656
o Meeting ID: 940 5928 7404
o Password: 353809

- Register here for a three-part Project ECHO webinar series with just-in-time training about monkeypox testing, vaccination, and treatment, hosted by Dartmouth Health in collaboration with the NH DPHS (see attached flyer). This training will review how to conduct intradermal injections.
• For any questions regarding this notification, please call the NH DHHS, DPHS, Bureau of Infectious Disease Control at (603) 271-4496 during business hours (8:00 a.m. – 4:30 p.m.).

• If you are calling after hours or on the weekend, please call the New Hampshire Hospital switchboard at (603) 271-5300 and request the Public Health Professional on-call.

• To change your contact information in the NH Health Alert Network, please send an email to DHHS.Health.Alert@dhhs.nh.gov.

Status: Actual
Message Type: Alert
Severity: Moderate
Sensitivity: Not Sensitive
Message Identifier: NH-HAN 20220810
Delivery Time: 12 hours
Acknowledgement: No
Distribution Method: Email, Fax
Distributed to: Physicians, Physician Assistants, Practice Managers, Infection Control Practitioners, Infectious Disease Specialists, Community Health Centers, Hospitals, Hospital CEOs, Hospital Emergency Departments, EMS, Nurses, NHHA, Pharmacists, Laboratory Response Network, Manchester Health Department, Nashua Health Department, Public Health Networks, DHHS Outbreak Team, DPHS Investigation Team, DPHS Management Team, Northeast State Epidemiologists, Zoonotic Alert Team, Health Officers, Deputy Health Officers, MRC, NH Schools, EWIDS, Dialysis & Transplant Clinics, STD Clinics, Immunization Practices, Travel Centers, Influenza Sentinels, Urgent Care Centers, Ambulatory Surgical Centers, Walk-in Clinics, Poison Center, Alcohol and Other Drug Treatment Centers, Long-Term Care Facilities, Community Mental Health Centers, Health Departments, Internal Medicine, Occupational Health, Gastroenterology, Schools and Daycare Providers, Regional Public Health Networks, Environmental Services, Family Planning Programs, Department of Corrections, Home Care Providers, Local and State Partners, Area Agencies

From: Benjamin P. Chan, MD, MPH; State Epidemiologist
Originating Agency: NH Department of Health and Human Services, Division of Public Health Services

Attachments: Project ECHO – Just In Time: Testing, Vaccination, and Treatment for Monkeypox
Just in time: Testing, Vaccination, and Treatment for Monkeypox

Course Description

The explosive global outbreak of Monkeypox has occurred while we are transitioning our COVID pandemic response from its emergency phase. The WHO has now declared Monkeypox a Public Health Emergency of international Concern that demonstrates we must now turn our attention to all available emerging evidence to become experts in control measures. This Project Echo session is a just in time, crash course about the epidemiology, strategies for prevention and medical countermeasures.

Who Should Attend

Clinicians, Nurses, PAs, LNAs, MAs, CHWs, and others in clinical settings in New Hampshire with interest (All states are welcome, but the ECHO will focus on NH recommendations)

Schedule

<table>
<thead>
<tr>
<th>Date</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/17/2022</td>
<td>Efficient effective testing</td>
</tr>
<tr>
<td>8/24/2022</td>
<td>Vaccine: PEP and PrEP: This session will be followed by a 30-minutes just-in-time training for how to give intradermal vaccination. Stay on if you are someone who may be giving the vaccine yourself, are supervising a team that does, or want to be able to address your patients’ concerns about the administration.</td>
</tr>
<tr>
<td>8/31/2022</td>
<td>Treatment: TPOXX and beyond</td>
</tr>
</tbody>
</table>

Questions?

Email: ECHO@hitchcock.org
Website: https://go.d-h.org/project-echo

Registration Information

To register, visit: https://echo.zoom.us/meeting/register/tZYsdOuorzkoEtCtQzp3oWQclFc_Cup7pJaa

Sessions are free or charge

What is Project ECHO?

Project ECHO (Extension for Community Healthcare Outcomes) is a telementoring model. Virtual technology is used to support case-based learning and provide education. This will assist participants to care for more people right where they live.

Benefits

- Participants learn from experts
- Participants learn from each other
- Experts learn from participants as best practices emerge

Moving Knowledge, Not People

Subject Matter Experts
- Share knowledge
- Acquire new knowledge
- Facilitate a network

ECHO Participants
- Acquire new knowledge
- Gain confidence
- Join a network

People Reached
- Advance equity
- Increase access to resources
- Earlier identification of those in need

Dartmouth Health
The medical screening questions below are to support clinics screening for contraindications and precautions to the JYNNEOS vaccination. This is a suggested list of baseline screening questions which can be implemented or modified as appropriate under a vaccine clinic’s medical direction. Please review and be familiar with CDC’s JYNNEOS vaccine contraindications and precautions. ([https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#safety](https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#safety))

### SECTION 1: VACCINE RECIPIENT INFORMATION

<table>
<thead>
<tr>
<th>Last Name:</th>
<th>First and Middle Initial:</th>
<th>Date of Birth:</th>
<th>Age (Years):</th>
</tr>
</thead>
</table>

### SECTION 2: JYNNEOS™ VACCINE SCREENING QUESTIONS

Please answer the following questions.

<table>
<thead>
<tr>
<th>1. Are you feeling sick today?</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Have you had a serious allergic reaction (e.g., anaphylaxis) after a previous dose of the JYNNEOS vaccine?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>3. Do you have a history of a severe allergic reaction to aminoglycoside antibiotics (such as gentamicin, amikacin, or tobramycin)?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>4. Do you have a history of a severe allergic reaction to fluoroquinolone antibiotics (such as ciprofloxacin, levofloxacin, or moxifloxacin)?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>5. Do you have a history of a severe allergic reaction to chick or egg protein <strong>AND</strong> are you currently avoiding exposure to all chicken or egg products?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>6. Have you been diagnosed with confirmed monkeypox virus infection during the 2022 outbreak?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>7. Do you have a history of developing keloid scars on your skin?</td>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>

Responses have been reviewed and verified by (vaccinator’s name): ___________________________
Adding or Receiving JYNNEOS™ Vaccine Inventory in the NH Immunization Information System (NHIIS)

Directly Shipped Vaccines to Healthcare Providers from the Strategic Stockpile

Upon receipt of the JYNNEOS™ vaccine, please check the packing list against the inventory to ensure everything you receive is correct, and store the vaccine in your freezer to maintain proper temperature (see applicable instructions on the Vaccine Storage and Handling Guidelines document). Next, you will need to add the vaccine into the NH Immunization Information System (NHIIS), as inventory per the following instructions. **Note:** You will have to enter your inventory manually, as you will not receive a blue hyperlink to select and receive inventory.

How you manually enter the JYNNEOS™ vaccine inventory into the NHIIS:

When the vaccine comes directly from the Strategic Stockpile, you will not receive a blue hyperlink to select and receive, but will have to enter it manually. Make sure to check the packing list against the inventory to ensure everything you receive is correct.

1. To begin adding on-hand inventory, select the **Inventory** menu.
2. Next, select the **Vaccines** menu to expand the menu options.
3. Select **On-Hand** from the list of menu options to navigate to the **Vaccine Inventory** screen.
4. Select **Add New Inventory**.

5. The first thing, to make note of, is the date will populate automatically to the current date in the **Date** field.
6. You can change the date by typing the correct date into the **Date** field using the format of two-digit month, two-digit day and four-digit year (MM/DD/YYYY).
7. To populate the time, left double click in the time field.
8. Next, select the **Inventory Location** drop down arrow.
9. Select the **PAN Inventory Location** from the list of options.
10. Select the **Vaccine | Mfg. | NDC | Brand** drop down arrow and select **Smallpox Monkeypox**.
11. Remember to ensure the NDC numbers match exactly.
12. Type the lot number into the Lot Number field and the expiration date in the Expiration Date field.
13. Select the Funding Source drop down arrow and select PAN as the source.
14. Enter the number of doses received in this shipment into the Doses Adjusted field.

15. Select Create as the final step in adding this shipment of JYNNEOS™ to your on hand inventory.

**Directly Shipped Vaccines to Healthcare Providers from New Hampshire Immunization Program (NHIP)**

**JYNNEOS™ Vaccine Ordering**

NHIP will be ordering the JYNNEOS™ vaccine on behalf of healthcare providers so you do not need to place an order in NHIIS. However, the following steps are required to transfer this vaccine into your vaccine inventory.

**Receiving JYNNEOS™ Vaccine inventory as transfer in the NHIIS**

1. To receive the JYNNEOS™ transfer in NHIIS, select the Inventory tree button on the left.
2. Next, select the Vaccines tree view to expand the menu options.
3. From the list of menu options, select On Hand to navigate to the Vaccine Inventory On-Hand screen.
4. Select the blue hyperlink ‘There is 1 Pending Inventory Transfer’ to proceed.
5. The **Source Location** will be **PAN: <Your Clinic Name>**
6. Select **Received** next to the JYNNEOS™ vaccine and enter the received Date and Time. Select OK.

7. Enter the date and time you actually received the vaccine.
8. This will add the inventory to the vaccine on hand.

**Please contact** [nhiis.support@dhhs.nh.gov](mailto:nhiis.support@dhhs.nh.gov) with any NHIIS-related questions.
Choose not to Participate in the New Hampshire Immunization/Vaccination Registry

☐ I choose not to participate in the New Hampshire immunization/vaccination registry.

☐ I choose not to have my child participate in the New Hampshire immunization/vaccination registry.

I understand that this decision will not prevent me or my child from receiving immunizations.

I understand that I may reverse my decision at any time by completing a “Reverse Previous Decision not to Participate in the New Hampshire Immunization/Vaccination Registry” form provided by my current health care provider.

I understand that my or my child’s immunization/vaccination information will not be released to the New Hampshire immunization/vaccination registry.

DATE: ________________________________

PATIENT NAME (printed): ___________________________ Date of Birth ____________

PATIENT NAME (signature): ____________________________________________

GUARDIAN NAME if person is under the age of 18 years (printed): ____________________________

GUARDIAN NAME if person is under the age of 18 years (signature): ____________________________

WITNESS by current health care provider: ____________________________________________

Patients who choose to decline participation in the registry are not relieved from the obligation to comply with current immunization requirements set forth in RSA 141-C:20-a and He-P 301.14.

To be completed by current health care provider:

Date entered into electronic medical record: ____________________________

Initials: ____________

(FORM: Opt-Out; 3/16)
NOTE: Your healthcare agency will need to be obtain an order by your prescribing healthcare provider PRIOR to administering the JYNNEOS™ vaccine. Ensure understanding of emergency protocols and medications in the unlikely event of an adverse reaction. Sample emergency protocols for adverse reactions are available at: Medical Management of Vaccine Reactions in Adults in a Community Setting (immunize.org) (https://www.immunize.org/catg.d/p3082.pdf)

Template vaccination standing orders are available here (under “Related Resources”):
https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html

Recommended Administration Routes for JYNNEOS™ Vaccine:

In August 2022, the federal government changed its administration strategy for the JYNNEOS™ vaccine. You can find the recommendations here. (https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html)

The recommendations are as follows:

For persons 18 years of age and older:

- Administer two doses (0.1 mL each) by intradermal injection 28 days apart.

For persons less than 18 years of age, or persons of any age with a history of developing keloid scars:

- Administer two doses (0.5 mL each) by subcutaneous injection 28 days apart.

JYNNEOS™ Intradermal Administration: Persons 18+ Years of Age:

This section provides guidance on intradermal administration of the JYNNEOS™ vaccine, by NH healthcare providers.

JYNNEOS™ is a two dose series, administered intradermally, 28 days apart. Administer 0.1 mL per dose with a 1 mL syringe (preferably a low dead volume syringe, i.e. tuberculin syringe) using a 26-28 gauge needle.
JYNNEOS™ Intradermal Administration: Individuals 18+ Years of Age: (continued):

The preferred injection site is the volar (inner) aspect of the forearm, halfway between elbow and wrist.

- Cleanse the injection site with a sterile alcohol wipe.
- Position the needle, bevel facing up, and insert the needle at a 5-15 degree angle into the dermis as shown below (JYNNEOS™ Vaccine | Monkeypox | Poxvirus | CDC).
  - https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#resources
- Slowly inject 0.1 mL intradermally. A wheal (i.e., pale elevation or bubble in skin) should form when advancing the plunger during intradermal injection.
  - If a wheal does not appear,
    - The dose may have been inadvertently administered as a subcutaneous injection, or
    - The vaccine liquid may have leaked out and resulted in lower-than-authorized dose administered.
    - You may need to administer a repeat dose right away.
  - Refer to CDC’s guidance on how to manage these and other vaccine administration errors. (https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/errors-deviations.html)

Review the training materials on how to administer an intradermal injection:

- Video: https://www.youtube.com/watch?v=TLv1mR6mECQ.
- Written Instructions with pictures:
  - https://journals.lww.com/nursing/Citation/2006/06000/Administering_an_intradermal_injection.16.aspx #:~:text=%E2%97%82Pull%20the%20skin%20taut,area%20on%20the%20skin%20's%20surface.
**Intradermal (ID) Injection Guidelines:**

*Injection Route:*

- **Injection Sites:**
  - Anterior aspect of the forearm
  - Upper chest
  - Upper back/Back of arm

*Injection Procedure:*

- Spread the skin taut, and insert the needle tip at a 10-15° angle.
- Inject medication slowly. If a wheal does not appear, it was administered in the subcutaneous tissue.

Source adapted from Becton Dickinson; MPS_HY_Intradermal-injection-guidelines-poster.IM.EN(1).pdf

---

**JYNNEOS™ Subcutaneous Administration: Persons Less Than 18 Years of Age or Persons of Any Age that Have a History of Developing Keloid Scars:**

This section provides guidance on **subcutaneous administration** for the JYNNEOS™, by NH healthcare providers.

Starting August 9, 2022, the FDA authorized JYNNEOS™ for use in persons younger than 18 years of age, under a FDA Emergency Use Authorization (EUA). The vaccine is a two dose series (0.5 mL per dose) administered subcutaneously 28 days apart. ([Jynneos™ Health Care Provider Fact Sheet 08092022 (fda.gov)](https://www.fda.gov/media/160774/download). Administer each dose using a 23-25 gauge, 5/8 inch needle for all subcutaneous injections. ([https://www.fda.gov/media/160774/download](https://www.fda.gov/media/160774/download)

The preferred injection site is into the fatty tissue over the triceps area in the upper arm (see image below).

- Cleanse the injection site with a sterile alcohol wipe.
Pinch up the fatty tissue over the triceps, insert the needle at a 45-degree angle, and then inject the vaccine dose.

Review CDC’s training video for instructions on how to administer a subcutaneous injection:

- [https://www.youtube.com/watch?v=R5jd4SDEcsA](https://www.youtube.com/watch?v=R5jd4SDEcsA)

**Screening and Precautions for Both Subcutaneous and Intradermal Vaccinations**

- Screen the vaccine recipient for illness or symptoms of monkeypox, including the presence of a skin rash or lesions.

- If symptoms are present, the vaccine recipient should isolate and be evaluated for monkeypox testing, especially if there is a new skin rash or lesions.

- If the vaccine recipient does NOT have symptoms, they are not considered contagious, even if exposed to the monkeypox virus. Healthcare personnel should use universal precautions and follow ACIP’s general guidelines for Vaccine Administration. ([https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html))

- Screen the vaccine recipient for vaccine precautions or contraindications per CDC guidance. ([https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#safety](https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#safety))
JYNNEOS™ Administration Checklist

- Remove a vial from storage and bring to room temperature. Once thawed, **do not refreeze**. The vaccine should be kept at +2°C to +8°C (+36°F to +46°F) for up to 8 weeks if not punctured. If using vial for multi-dose (intradermal injections should have 5 doses per vial) the vial can be kept at +2°C to +8°C (+36°F to +46°F) after initial puncture for up to 8 hours. More information is available in the included NH document: “JYNNEOS™ Storage and Handling Guidelines”.

<table>
<thead>
<tr>
<th>Medical condition or history</th>
<th>Interim guidance</th>
<th>Suggested action(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of JYNNEOS</td>
<td>Contraindication</td>
<td>Do not vaccinate. Referral to an allergist-immunologist should be considered to assess the risks versus benefits of administering a dose.</td>
</tr>
<tr>
<td>History of severe allergic reaction (e.g., anaphylaxis) following gentamicin or ciprofloxacin¹</td>
<td>Precaution</td>
<td>Discuss risks and benefits with potential recipients. They may be vaccinated with a 30-minute observation period. Alternatively, vaccination can be delayed until an allergist-immunologist is consulted, but the impact of delaying vaccination should be considered.</td>
</tr>
<tr>
<td>History of severe allergic reaction (e.g., anaphylaxis) to chicken or egg protein AND are currently avoiding exposure to all chicken or egg products¹</td>
<td>Precaution</td>
<td>Discuss risks and benefits with potential recipients. They may be vaccinated with a 30-minute observation period. Alternatively, vaccination can be delayed until an allergist-immunologist is consulted, but the impact of delaying vaccination should be considered.</td>
</tr>
<tr>
<td>Moderate or severe acute illness, with or without fever</td>
<td>Precaution</td>
<td>Consider deferring vaccination until the acute illness has improved.</td>
</tr>
</tbody>
</table>

¹ JYNNEOS vaccine contains small amounts of gentamicin and ciprofloxacin and is produced using chicken embryo fibroblast cells.
Inspect vaccine. When thawed, JYNNEOS™ is a milky, light yellow to pale white colored suspension. Visually inspect for particulate matter and discoloration prior to administration. If either of these conditions exists, do not administer the vaccine.

- Provide the Jynneos™ EUA “Fact Sheet for Recipients and Caregivers”.
  [https://www.fda.gov/media/160773/download](https://www.fda.gov/media/160773/download)

- Verify the identity of the vaccine recipient and provide the individual with the opportunity to Opt Out of the NH Immunization Information System (NHIIS).
  
  If the individual chooses NOT to participate in the NHIIS, the individual MUST complete and sign the "Choose Not to Participate in the NHIIS" form and keep this in the individual’s medical record.

  NOTE: Do not send this opt out form to the state.

- Screen the vaccine recipient for vaccine contraindications or precautions.

- Swirl the vial gently before use for at least 30 seconds before withdrawing a dose.
  - If performing an intradermal injection: Withdraw 0.1 mL into a sterile syringe (26-28 Gauge Needle less than 1/2” length).
    - For new vials: On the vial, write the date and time, the vial was first punctured.
    - Refrigerate vial to maintain viability of vaccine.
    - Discard vial after 8 hours from first puncture.
    - Do NOT combine residual vaccine from multiple vials to obtain a dose.
  - If performing a subcutaneous injection: Withdraw 0.5 mL into a sterile syringe (23-25 Gauge Needle 5/8” length).

- Choose the site for vaccination.
  - If performing an intradermal injection: Site location is the volar (inner) aspect of the forearm, halfway between elbow and wrist.
  - If performing a subcutaneous injection: Recommended site location is over the triceps area of the upper arm.

- Prepare site for vaccination with an alcohol wipe, using a circular motion, from the center of your injection site, outward, in a 2” to 3” circle. Allow alcohol to dry.

- Administer the JYNNEOS™ vaccine as outlined above.

- Follow your healthcare facility protocols for administering subcutaneous or intradermal vaccination and proper vaccine administration documentation in your facility’s EMR and in NHIIS.

- If completing the encounter for the first dose of the series, ensure the individual has an appointment scheduled to receive the second dose (28-day minimum interval). Observe the vaccine recipient for 30 minutes, if the individual has a vaccine precaution. Observe for 15 minutes for all other individuals. Assist with and report any adverse event: Vaccine Adverse Event Reporting System (VAERS) (hhs.gov) [https://vaers.hhs.gov/index.html](https://vaers.hhs.gov/index.html)
Documenting JYNNEOS™ in the NHIIS (Patient has elected to opt-out)

2. You will stop here and NOT enter the patient information into the NHIIS. You will adjust inventory using the Inventory Adjustment reason Patient Opted Out, making sure not to record any information into the NHIIS. This process ensures your inventory is accurate with current vaccine administration, while maintaining the patient’s request not to enter their information into the system. See specific Inventory Adjustment procedures for intradermal and subcutaneous injections later in this document.

Documenting a Dose of JYNNEOS™ in the NHIIS (Individual/Patient has NOT elected to opt-out)

1. Log into Patient menu in the NHIIS and Search for the patient’s name using the best practices criteria.
2. Once you have created or verified the patient, please select the Immunizations section of the NHIIS menu.
3. This will take you to the Immunizations Home page. Go to the Select Action button and in the drop down select Add Vaccine.
4. Ensure you select the correct clinic from the dropdown menu.
5. Enter the Vaccination Date and Prescribed By, if they are on the list in the drop down.
6. Select the **Display All Vaccines** button. Select the **Smallpox Monkeypox** vaccine from the Vaccine drop down.

The **JYNNEOUS™** vaccine is the Smallpox Monkeypox vaccine in this screen.

7. Select **Create and Administer** at the top and it will take you to the **Administer** screen.

8. On the **Administer** screen, it is very important that you select the **Vaccination Time** field. This is not a required field, so it will allow you to skip past it. If you do, it will default the time to midnight, and that will affect reconciliation counts.
Documenting JYNNEOS™ Vaccine Administration
Subcutaneous and Intradermal Injections

Make sure you enter the Vaccination Time on the Administer screen!

9. Fill in the Administered By from the drop down. If the vaccine administrator is not in the drop down list, please fill out a Change of Staff form and send it to NHIIS to have them added, and finish documenting the vaccination.

10. Select the Mfg. | Lot | Exp. Date | Funding Source | Inv. Loc. | NCD | Brand
   This will display all on-hand inventory lot numbers. Choose the lot number of the vaccination given.
   This will populate the remaining fields.

Documenting Administration of an Intradermal or Subcutaneous Vaccine

If documenting a subcutaneous administration:

a. In the Administer screen, the dosage box defaults to 0.10 mL for the JYNNEOS™ intradermal dose. Update the value to 0.50 mL manually for a subcutaneous dose administration (or subsequent subcutaneous dose).

b. In the Route field, change the method from Intradermal to Subcutaneous.

c. Select Update at the top of the page.

If documenting an intradermal administration:

a. Verify the information is correct in the Administer screen and select Update at the top of the page.
b. Changing the dose volume will deduct one vial (a 0.5ml dose) from the lot number, **not a 0.1 mL dose**. You must update your vaccine **Inventory On-Hand** with correct reason codes to account for the four additional doses to be used from this vial.

The system will display “No matching Inventory found” if you have not added the Smallpox Monkeypox Vaccine (JYNNEOS™) to your inventory manually or received the vaccine.

c. Once you select **Update** for an intradermal or subcutaneous administration, it will take you back to the **Immunization Home** screen. You will see the Smallpox Monkeypox Vaccine as administered. If you need to edit any information, you can select the **Update** button to go back into the vaccination.
Managing JYNNEOS™ Vaccine Inventory When Administering Intradermal Doses

As the dosage administered for intradermal doses is a 0.1 mL dose, you will have to adjust the vaccine inventory to reflect the proper number of immunizations drawn from a single vial. When administering a 0.1 mL dose, you will add four (4) additional doses to your Smallpox Monkeypox inventory. The NHIIS sees all inventory as one full dose and does not recognize increments drawn into a syringe.

Creating Additional Doses

1. Navigate to the Inventory Module and Select Vaccines → On-Hand.
2. Select the Action and Adjustment for the Smallpox Monkeypox vaccine.

3. Select the Reason Dose Count Variance Multi-Dose Vial.
   a. Select the Add option as the modification reason.
   b. Enter the amount of JYNNEOUS™ Intradermal Doses Adjusted and select Create.
4. NOTE: In order to account for the additional doses with intradermal doses, you MUST create them when you administer more than one vaccine from a vial, up to four additional doses per vial (five total doses per vial). Please contact your vaccine managers to perform the inventory adjustment if you do not have access in NHIIS.
5. Please ensure you increase your inventory dose count by one vial (four additional doses) at a time. This will reduce the number of potentially wasted doses.

**Reporting Wastage for Additional Intradermal JYNNEOS™ Doses**

1. Navigate to the Inventory Module and Select Vaccines → On-Hand.
2. Select Action and Adjustment for the Smallpox Monkeypox vaccine.
3. Select the Reason **VTRKS-Open Vial But All Doses Not Administered. Subtract** will be the default option as modification reason. Enter the amount of **Doses Adjusted** and enter into the **Comment** field: **Date, Initials and JYNNEOUS™ Intradermal Additional Doses Wastage** then select **Create**.

4. This will remove any of the unused additional 0.1 mL doses added.
5. To minimize wastage, add one vial (four additional doses) at a time and strive to have **five patients available** to use all the doses in the vial.
<table>
<thead>
<tr>
<th>Vaccine Information Card</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please keep this record card, which includes medical information about the vaccines you have received.</td>
</tr>
<tr>
<td>NH DEPARTMENT OF HEALTH &amp; HUMAN SERVICES</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Birth</td>
</tr>
<tr>
<td>MM / DD / YYYY</td>
</tr>
<tr>
<td>Provider (Name, Address, Phone)</td>
</tr>
</tbody>
</table>

Please keep this record card, which includes medical information about the vaccines you have received.

Por favor, guarde esta tarjeta de registro, que incluye información médica sobre las vacunas que ha recibido.
<table>
<thead>
<tr>
<th>Vaccine Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot #/Manufacturer</td>
</tr>
<tr>
<td>Date</td>
</tr>
<tr>
<td>Admin By</td>
</tr>
<tr>
<td>Date</td>
</tr>
</tbody>
</table>

This vaccine information will be stored in the NH Vaccine registry, NHIIS, unless you choose not to participate. To obtain a copy of your immunization records, contact your participating health care provider, or contact the NH Immunization Program at (603) 271-4028.

View your immunization records at [https://nhiis-prod.dhhs.nh.gov/nhiis/Login.aspx](https://nhiis-prod.dhhs.nh.gov/nhiis/Login.aspx)